受强制性开放获取政策约束的文章 - Huan Xie了解详情
可在其他位置公开访问的文章：27 篇
Nanoparticles in daily life: applications, toxicity and regulations
R Gupta, H Xie
Journal of Environmental Pathology, Toxicology and Oncology 37 (3), 2018
强制性开放获取政策： US National Institutes of Health
Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy
H Xie, P Diagaradjane, AA Deorukhkar, B Goins, A Bao, WT Phillips, ...
International journal of nanomedicine, 259-269, 2011
强制性开放获取政策： US National Institutes of Health
Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells
H Xie, B Goins, A Bao, ZJ Wang, WT Phillips
International journal of nanomedicine, 2227-2238, 2012
强制性开放获取政策： US National Institutes of Health
Development of PLGA-based itraconazole injectable nanospheres for sustained release
X Bian, S Liang, J John, CH Hsiao, X Wei, D Liang, H Xie
International Journal of Nanomedicine, 4521-4531, 2013
强制性开放获取政策： US National Institutes of Health
Hypoxia-targeted gold nanorods for cancer photothermal therapy
Y Chen, X Bian, M Aliru, AA Deorukhkar, O Ekpenyong, S Liang, J John, ...
Oncotarget 9 (41), 26556, 2018
强制性开放获取政策： US Department of Defense, US National Institutes of Health
In vitro dissolution considerations associated with nano drug delivery systems
R Gupta, Y Chen, H Xie
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 13 (6 …, 2021
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
Determination of proline in human serum by a robust LC‐MS/MS method: application to identification of human metabolites as candidate biomarkers for esophageal cancer early …
S Liang, B Sanchez‐Espiridion, H Xie, J Ma, X Wu, D Liang
Biomedical Chromatography 29 (4), 570-577, 2015
强制性开放获取政策： US National Institutes of Health
Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics
M Sarkar, Y Wang, O Ekpenyong, D Liang, H Xie
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 15 (2 …, 2023
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
Designing a mucoadhesive chemopatch to ablate oral dysplasia for cancer prevention
X Liu, Q Li, Y Wang, M Crawford, PK Bhupal, X Gao, H Xie, D Liang, ...
Small 18 (25), 2201561, 2022
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer
S Liang, X Bian, D Liang, JC Sivils, LM Neckers, MB Cox, H Xie
Pharmaceutical development and technology 21 (1), 121-126, 2016
强制性开放获取政策： US National Institutes of Health
Inactivation of ID 4 promotes a CRPC phenotype with constitutive AR activation through FKBP 52
JB Joshi, D Patel, DJ Morton, P Sharma, J Zou, D Hewa Bostanthirige, ...
Molecular oncology 11 (4), 337-357, 2017
强制性开放获取政策： US National Institutes of Health
Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats
X Gao, RYL Tsai, J Ma, PK Bhupal, X Liu, D Liang, H Xie
Journal of Chromatography B 1136, 121930, 2020
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
Pre-clinical pharmacokinetics, tissue distribution and physicochemical studies of CLBQ14, a novel methionine aminopeptidase inhibitor for the treatment of infectious diseases
O Ekpenyong, X Gao, J Ma, C Cooper, L Nguyen, OA Olaleye, D Liang, ...
Drug Design, Development and Therapy, 1263-1277, 2020
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
A simple, sensitive and reliable LC-MS/MS method for the determination of 7-bromo-5-chloroquinolin-8-ol (CLBQ14), a potent and selective inhibitor of methionine aminopeptidases …
O Ekpenyong, C Cooper, J Ma, D Liang, O Olaleye, H Xie
Journal of Chromatography B 1097, 35-43, 2018
强制性开放获取政策： US National Institutes of Health
Surfactant mediated accelerated and discriminatory in vitro drug release method for PLGA nanoparticles of poorly water-soluble drug
R Gupta, Y Chen, M Sarkar, H Xie
Pharmaceuticals 15 (12), 1489, 2022
强制性开放获取政策： Cancer Prevention Research Institute of Texas, USA
Development and validation of a sensitive LC/MS/MS method for the determination of γ‐tocotrienol in rat plasma: application to pharmacokinetic studies
S Liang, X Bian, J Ma, M Arogunjo, AA Deorukhkar, S Krishnan, H Xie
Biomedical Chromatography 27 (1), 58-66, 2013
强制性开放获取政策： US National Institutes of Health
Metabolite Identification of a novel anti-leishmanial agent OJT007 in rat liver microsomes using LC-MS/MS
ME Rincon Nigro, T Du, S Gao, M Kaur, H Xie, OA Olaleye, D Liang
Molecules 27 (9), 2854, 2022
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
Quantification of a new anti-cancer molecule MJC13 using a rapid, sensitive, and reliable liquid chromatography-tandem mass spectrometry method
S Liang, X Bian, J Sivils, LM Neckers, MB Cox, H Xie
American journal of modern chromatography 1 (1), 1, 2014
强制性开放获取政策： US National Institutes of Health
Bioanalytical assay development and validation for the pharmacokinetic study of gmc1, a novel fkbp52 co-chaperone inhibitor for castration resistant prostate cancer
O Ekpenyong, C Cooper, J Ma, NC Guy, AN Payan, F Ban, A Cherkasov, ...
Pharmaceuticals 13 (11), 386, 2020
强制性开放获取政策： US Department of Defense, US National Institutes of Health, Cancer …
Preclinical development of brain permeable ERβ agonist for the treatment of glioblastoma
UP Pratap, M Tidwell, HU Balinda, NA Clanton, X Yang, ...
Molecular cancer therapeutics 22 (11), 1248-1260, 2023
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
出版信息和资助信息由计算机程序自动确定